Leveraging Adthena’s Whole Market View, this analysis explores recent trends in Google Ads for the AUS Research and Development category from the last month. Our Data Analyst, Ask Arlo provides commentary on key findings.
See how often AIOs appear and how search intent is distributed across buying signals.
How often a Google AI overview appears on search terms relevant to this category.
| Frequency | Percentage |
|---|---|
| Frequency | 24.7010250569 |
| 75.2989749431 |
A complex query is a longer, more detailed search that often contains multiple keywords, specific conditions, or multi-part questions.
| Frequency | Percentage |
|---|---|
| Frequency | 8 |
| 92 |
Copyright © Adthena. All rights reserved.
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| monash.edu | 32.82 |
| unimelb.edu.au | 20.66 |
| tri.edu.au | 14.91 |
| uq.edu.au | 14.22 |
| uts.edu.au | 9.88 |
| naturecareers.com | 2.69 |
| hudson.org.au | 1.74 |
| careergirls.org | 0.92 |
| rmit.edu.au | 0.61 |
| hri.org.au | 0.53 |
| others | 1.02 |
Copyright © Adthena. All rights reserved.
Monash.edu leads with 32.82% click share, followed by unimelb.edu.au at 20.66%. Others collectively hold 1.02%, highlighting diverse competition in the PPC landscape.
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | unimelb.edu.au | uts.edu.au | monash.edu | tri.edu.au | hudson.org.au | uq.edu.au | rmit.edu.au | coursera.org | naturecareers.com | medworld.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/08/01 | 18.98% | 7.16% | 35.35% | 4.06% | 0.44% | 26.48% | 0% | 0% | 3.56% | 0.28% |
| 2026/08/02 | 0% | 0% | 0% | 9.37% | 3.46% | 65.35% | 0% | 0% | 9.27% | 1.33% |
| 2026/08/03 | 0% | 0% | 61.67% | 9.57% | 5.93% | 0% | 0% | 0% | 3.72% | 3.97% |
| 2026/08/04 | 10.8% | 22.62% | 27.55% | 5.48% | 0.68% | 12.98% | 12.4% | 0% | 4.45% | 1.33% |
| 2026/08/05 | 22.46% | 0% | 10.76% | 5.08% | 0.5% | 59.53% | 0% | 0% | 0.98% | 0.21% |
| 2026/08/06 | 0% | 0% | 65.38% | 18.48% | 2.25% | 0% | 0% | 0% | 2.35% | 0.48% |
| 2026/08/07 | 0% | 38.44% | 46.82% | 11.17% | 1.04% | 0% | 0% | 0% | 1.69% | 0.68% |
| 2026/08/08 | 32% | 33.52% | 0% | 26.38% | 2.81% | 0% | 0% | 0% | 4.41% | 0.59% |
| 2026/08/09 | 0% | 18.18% | 66.79% | 13.18% | 1.25% | 0% | 0% | 0% | 0% | 0.41% |
| 2026/08/10 | 0% | 0% | 56.61% | 13.6% | 1.3% | 27.43% | 0% | 0% | 0% | 0.85% |
| 2026/08/11 | 35.3% | 0% | 30.68% | 6.61% | 0.35% | 26.76% | 0% | 0% | 0% | 0.21% |
| 2026/08/12 | 22.59% | 0% | 68.69% | 7.2% | 0.7% | 0% | 0% | 0% | 0% | 0.42% |
| 2026/08/13 | 47.38% | 33.08% | 16.28% | 3.26% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/14 | 44.37% | 46.47% | 0% | 9.16% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/15 | 51.96% | 18.14% | 26.33% | 3.58% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/16 | 18.89% | 19.78% | 57.43% | 3.9% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/17 | 0% | 0% | 73.88% | 22.83% | 0% | 0% | 0% | 0% | 3.29% | 0% |
| 2026/08/18 | 29.11% | 0% | 60.02% | 9.53% | 0% | 0% | 0% | 0% | 1.34% | 0% |
| 2026/08/19 | 0% | 0% | 86.71% | 9.43% | 0% | 0% | 0% | 0% | 3.86% | 0% |
| 2026/08/20 | 26.84% | 28.11% | 40.81% | 3.01% | 0% | 0% | 0% | 0% | 1.23% | 0% |
| 2026/08/21 | 0% | 0% | 90.58% | 6.68% | 0% | 0% | 0% | 0% | 2.74% | 0% |
| 2026/08/22 | 36.22% | 0% | 18.36% | 1.35% | 0% | 43.51% | 0% | 0% | 0.55% | 0% |
| 2026/08/23 | 40.1% | 0% | 47.89% | 1.42% | 0.18% | 0% | 0% | 9.67% | 0.58% | 0% |
| 2026/08/24 | 37.27% | 29.28% | 30.86% | 1.57% | 0.2% | 0% | 0% | 0% | 0.64% | 0% |
| 2026/08/25 | 47.68% | 0% | 48.33% | 2.67% | 0.67% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/26 | 53.41% | 0% | 44.16% | 1.63% | 0.41% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/27 | 54.5% | 0% | 43.83% | 0.96% | 0.24% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/28 | 38.4% | 0% | 58.38% | 2.15% | 0.54% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/29 | 80.06% | 0% | 18.68% | 0.76% | 0.17% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/30 | 66.03% | 0% | 31.64% | 1.75% | 0.29% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/31 | 57.46% | 21.06% | 19.34% | 1.87% | 0.18% | 0% | 0% | 0% | 0% | 0% |
Copyright © Adthena. All rights reserved.
In August 2026, unimelb.edu.au’s PPC spend fluctuated, peaking at 80.06 on the 29th. Monash.edu saw a high of 90.58 on the 21st. Uq.edu.au and uts.edu.au had moderate variations, while tri.edu.au and naturecareers.com maintained low spend levels.
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/08/01 | 14 |
| 2026/08/02 | 11 |
| 2026/08/03 | 9 |
| 2026/08/04 | 13 |
| 2026/08/05 | 12 |
| 2026/08/06 | 7 |
| 2026/08/07 | 7 |
| 2026/08/08 | 7 |
| 2026/08/09 | 6 |
| 2026/08/10 | 6 |
| 2026/08/11 | 7 |
| 2026/08/12 | 6 |
| 2026/08/13 | 4 |
| 2026/08/14 | 3 |
| 2026/08/15 | 4 |
| 2026/08/16 | 4 |
| 2026/08/17 | 3 |
| 2026/08/18 | 4 |
| 2026/08/19 | 3 |
| 2026/08/20 | 5 |
| 2026/08/21 | 3 |
| 2026/08/22 | 5 |
| 2026/08/23 | 7 |
| 2026/08/24 | 7 |
| 2026/08/25 | 5 |
| 2026/08/26 | 5 |
| 2026/08/27 | 5 |
| 2026/08/28 | 5 |
| 2026/08/29 | 5 |
| 2026/08/30 | 5 |
| 2026/08/31 | 6 |
Copyright © Adthena. All rights reserved.
August began with 14 advertisers, dropping to 6 by month’s end. Mid-month saw a low of 3, but a slight recovery followed.
Here we’re looking at the Top 10 biggest industry movers by market share gains and losses for the last 30 days.
Copyright © Adthena. All rights reserved.
In the past month, unimelb.edu.au surged by 23.78%, while tri.edu.au plummeted by 14.83%. Monash.edu gained 10.16%, contrasting with uq.edu.au’s 9.5% drop.
Take a look at the Top 10 competitors in the industry by Share of Impressions over the last month.
| Date | unimelb.edu.au | uts.edu.au | monash.edu | tri.edu.au | hudson.org.au | uq.edu.au | careergirls.org | coursera.org | naturecareers.com | hri.org.au |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/08/01 | 17.76% | 8.88% | 21.67% | 9.33% | 1.58% | 26.64% | 0% | 0% | 8.62% | 2.26% |
| 2026/08/02 | 0% | 0% | 0% | 22.15% | 7.04% | 41.01% | 0% | 0% | 14.34% | 5.82% |
| 2026/08/03 | 0% | 0% | 34.66% | 21.3% | 14.44% | 0% | 0% | 0% | 9.39% | 3.37% |
| 2026/08/04 | 9.61% | 19.21% | 21.33% | 15.14% | 2.73% | 9.61% | 0% | 0% | 7.73% | 0.85% |
| 2026/08/05 | 20.68% | 0% | 8.41% | 15.22% | 2.16% | 48.26% | 0% | 0% | 3.42% | 0.61% |
| 2026/08/06 | 0% | 0% | 29.09% | 28.54% | 5.27% | 0% | 31.98% | 0% | 4.33% | 0% |
| 2026/08/07 | 0% | 29.54% | 32.79% | 27.28% | 4.19% | 0% | 0% | 0% | 4.88% | 0% |
| 2026/08/08 | 18.29% | 18.29% | 0% | 45.89% | 7.36% | 0% | 0% | 0% | 9.07% | 0% |
| 2026/08/09 | 0% | 17.76% | 43.34% | 32.81% | 5.04% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/10 | 0% | 0% | 43.34% | 32.28% | 5.04% | 17.76% | 0% | 0% | 0% | 0% |
| 2026/08/11 | 31.79% | 0% | 25.86% | 19.26% | 1.26% | 21.19% | 0% | 0% | 0% | 0% |
| 2026/08/12 | 21.55% | 0% | 52.6% | 21.37% | 2.56% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/13 | 45.04% | 30.03% | 15.01% | 9.92% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/14 | 37.58% | 37.58% | 0% | 24.84% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/15 | 51.01% | 17% | 20.75% | 11.24% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/16 | 19.6% | 19.6% | 47.84% | 12.96% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2026/08/17 | 0% | 0% | 46.37% | 45.97% | 0% | 0% | 0% | 0% | 7.66% | 0% |
| 2026/08/18 | 24.06% | 0% | 48.11% | 23.85% | 0% | 0% | 0% | 0% | 3.98% | 0% |
| 2026/08/19 | 0% | 0% | 66.86% | 22.1% | 0% | 0% | 0% | 0% | 11.05% | 0% |
| 2026/08/20 | 26.91% | 26.91% | 32.84% | 8.89% | 0% | 0% | 0% | 0% | 4.45% | 0% |
| 2026/08/21 | 0% | 0% | 71.11% | 19.26% | 0% | 0% | 0% | 0% | 9.63% | 0% |
| 2026/08/22 | 38.88% | 0% | 15.82% | 4.28% | 0% | 38.88% | 0% | 0% | 2.14% | 0% |
| 2026/08/23 | 37.52% | 0% | 43.03% | 4.13% | 0.37% | 0% | 0% | 12.51% | 2.07% | 0.37% |
| 2026/08/24 | 37.51% | 28.13% | 26.54% | 4.65% | 0.42% | 0% | 0% | 0% | 2.32% | 0.42% |
| 2026/08/25 | 49.06% | 0% | 39.92% | 8.11% | 1.46% | 0% | 0% | 0% | 0% | 1.46% |
| 2026/08/26 | 53.56% | 0% | 39.22% | 5.31% | 0.95% | 0% | 0% | 0% | 0% | 0.95% |
| 2026/08/27 | 54.8% | 0% | 40.56% | 3.02% | 0.54% | 0% | 0% | 0% | 0% | 1.08% |
| 2026/08/28 | 40.9% | 0% | 49.91% | 6.76% | 1.21% | 0% | 0% | 0% | 0% | 1.21% |
| 2026/08/29 | 79.19% | 0% | 16.11% | 2.57% | 1.34% | 0% | 0% | 0% | 0% | 0.78% |
| 2026/08/30 | 64.13% | 0% | 26.09% | 5.43% | 3.71% | 0% | 0% | 0% | 0% | 0.63% |
| 2026/08/31 | 51.47% | 25.74% | 15.7% | 5.78% | 0.93% | 0% | 0% | 0% | 0% | 0% |
Copyright © Adthena. All rights reserved.
In August 2026, unimelb.edu.au’s impression share fluctuated, peaking at 79.19% on the 29th. Monash.edu saw a high of 71.11% on the 21st. By month’s end, unimelb.edu.au led with 51.47%, while monash.edu dropped to 15.7%.
Ever wondered how your rivals’ ads are doing? Here we can see the top-performing ads in the industry over the last month.
Biotechnology courses from top universities and industry leaders. Learn Biotechnology online with courses like Industrial Biotechnology and Introduction...
Pharmaceutical Sci Innovation — Career pathways in biotech, pharmaceutical industry, research, and regulatory affairs. Explore cutting-edge medicinal chemistry with Monash's Pharmaceutical Science Degree. Industry Leaders.
The University of Melbourne — Biotechnology is a key 21st-century industry with strong, growing demand for specialists. Gain real-work experience, work with industry partners to solve biotech-related problems.
Study Biotechnology At UQ — Wherever Your Future Lies, Get There Faster With UQ's Master Of Biotechnology. Reach Your Full Potential & Master Your Career With A Postgraduate Degree From UQ. Teaching Excellence.
Where medical innovation happens at the intersection of science, technology & engineering. Pursue your postgraduate studies with a course at UTS Science. Think Outside The Box. A flexible approach.
Copyright © Adthena. All rights reserved.
In the competitive landscape of biotechnology education, Coursera, Monash, Melbourne, UQ, and UTS stand out. Coursera offers accessible online courses, while Monash and Melbourne emphasize industry connections and career pathways. UQ and UTS highlight postgraduate excellence and innovation, promising transformative educational experiences.
Imagine being able to instantly see your competitors Market Share, Share of Spend and their top performing ad copy so you can effectively benchmark your own performance.
Adthena’s PPC Market Share reports provide an instant view of performance insights across hundreds of sub-industries – so you can do just that.
How to use the AUS Pharma & Biotech Research and Development August 2026 Report
Think of these reports as a cheat sheet for your industry’s search landscape. Check out this short article for a breakdown of each report and how they can benefit your strategy.
Data within the AUS Pharma & Biotech Research and Development August 2026 Report is aggregated every month, highlighting the most significant changes from the previous period.
We use observed data from Google’s search results pages. With 20 million Google SERPs indexed per day. Adthena forms a global index of publicly available searches on Google.
On top of observed data, our data science models and patented technology expand on the insights through estimated metrics like market share, share of spend, and more.
We have 12 years of historical data across industries and our custom-built AI models learn from continuously updated data every day.
The AUS Pharma & Biotech Research and Development August 2026 Report is powered by Adthena’s Whole Market View, which is the patented technology that drives value for our 300 enterprise customers.
Our unique approach to search intelligence ingests Google’s Keyword Planner into its learning models, providing a more accurate and up-to-date view of keyword data compared to traditional panel data methods.
With daily data collection and updates, Adthena offers a closer-to-real-time view of the Google Ads auction, enabling timely insights and adjustments.
Adthena focuses specifically on Google Ads, providing a deep dive into the channel and offering detailed insights into its workings. By processing 10 TB of new data daily and employing AI and machine learning models to analyze millions of Google Ads searches per second, Adthena provides a comprehensive and in-depth view of the competitive landscape.
Learn more about our data accuracy
Yes. The AUS Pharma & Biotech Research and Development August 2026 Report aggregates data from across both device types and Google Shopping.
The AUS Pharma & Biotech Research and Development August 2026 Report is for enterprise brands and agencies who want quick and high-level, historical benchmarks that are easily digestible and reveal insights, trends and market winners relevant to their own industry.
Our search consultants can introduce you to data that is specific to your organization, based on the size of the relevant search term and competitor universe, and the geographies that need monitoring.
Complete the form below to get started.
Ask Arlo leverages real-time GenAI to answer customers’ questions about their own search data and receive instant, tailored responses and reports directly within the Adthena platform.
With millions of Google SERPs indexed every day, Arlo never misses a trick and makes sure you’re always up to date.
The data on this page is just a sample of the billions of data points we hold at Adthena. The insights generated by Ask Arlo, leverage real-time GenAI to answer questions about your search data.
Our search consultants can introduce you to Whole Market View data that is specific to your organization, based on the size of the relevant search term and competitor universe, and the locations that you need monitoring.